StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.33+5.27 (+7.63%)

Close on Nov 19, 2026Market cap $1.09BP/E –Yield –

Inhibrx Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Inhibrx Biosciences's free cash flow for the twelve months ending Sep 30, 2026 was -$132.70M. For fiscal 2025 it was -$129.83M. The highest annual figure on record is -$33.89M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$129.83M–
FY2024Dec 31, 2024-$197.01M–
FY2023Dec 31, 2023-$197.90M–
FY2022Dec 31, 2022-$115.99M–
FY2021Dec 31, 2021-$81.19M–
FY2020Dec 31, 2020-$49.33M–
FY2019Dec 31, 2019-$33.89M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$34.63M–
Q2 FY2026Jun 30, 2026-$29.92M–
Q1 FY2026Mar 31, 2026-$38.03M–
Q4 FY2025Dec 31, 2025-$30.12M–
Q3 FY2025Sep 30, 2025-$33.83M–
Q2 FY2025Jun 30, 2025-$29.95M–
Q1 FY2025Mar 31, 2025-$35.92M–
Q4 FY2024Dec 31, 2024-$43.74M–
Q3 FY2024Sep 30, 2024-$30.53M–
Q2 FY2024Jun 30, 2024-$58.57M–
Q1 FY2024Mar 31, 2024-$64.17M–
Q4 FY2023Dec 31, 2023-$60.26M–
Q3 FY2023Sep 30, 2023-$55.06M–
Q2 FY2023Jun 30, 2023-$42.62M–
Q1 FY2023Mar 31, 2023-$39.97M–
Q4 FY2022Dec 31, 2022-$30.87M–
Q3 FY2022Sep 30, 2022-$30.82M–
Q2 FY2022Jun 30, 2022-$27.24M–
Q1 FY2022Mar 31, 2022-$27.06M–
Q4 FY2021Dec 31, 2021-$22.89M–
Q3 FY2021Sep 30, 2021-$13.84M–
Q2 FY2021Jun 30, 2021-$22.79M–
Q1 FY2021Mar 31, 2021-$21.66M–
Q4 FY2020Dec 31, 2020-$16.00M–
Q3 FY2020Sep 30, 2020-$14.18M–
Q2 FY2020Jun 30, 2020-$11.67M–
Q1 FY2020Mar 31, 2020-$7.48M–
Q4 FY2019Dec 31, 2019-$12.28M–

More Inhibrx Biosciences figures

See a number that looks wrong?